TY - JOUR T1 - Multi-level modeling and multiple group analysis of disparities in continuity of care and viral suppression among Nigerian adolescents and youths living with HIV JF - medRxiv DO - 10.1101/2020.06.28.20141812 SP - 2020.06.28.20141812 AU - Okikiolu Abimbola Badejo AU - Christiana Noestlinger AU - Toyin Jolayemi AU - Juliet Adeola AU - Prosper Okonkwo AU - Sara Van Belle AU - Edwin Wouters AU - Marie Laga Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/29/2020.06.28.20141812.abstract N2 - Introduction Substantial disparities in care outcomes exist between different sub-groups of adolescents and youths living with HIV(ALHIV). Understanding variation in individual and health-facility characteristics could be key to identifying targets for interventions to reduce these disparities. We modeled variation in ALHIV retention in care and viral suppression, and quantified the extent to which individual and facility characteristics account for observed variations.Methods We included 1,177 young adolescents (10-14 years), 3,206 older adolescents (15-19 years) and 9,151 young adults (20-24 years) who were initiated on antiretroviral therapy (ART) between January 2015 and December 2017 across 124 healthcare facilities in Nigeria. For each age-group, we used multilevel modeling to partition observed variation of main outcomes(retention in care and viral suppression at 12 months post ART initiation) by individual (level one) and health facility (level two) characteristics. We used multiple group analysis to compare the effects of individual and facility characteristics across age-groups.Results Facility characteristics explained most of the observed variance in retention in care in all the age-groups, with smaller contributions from individual-level characteristics (14-22.22% vs 0 - 3.84%). For viral suppression, facility characteristics accounted for a higher proportion of variance in young adolescents (15.79%), but not in older adolescents (0%) and young adults(3.45%). Males were more likely to not be retained in care(aOR=1.28; p<0.001 young adults) and less likely to achieve viral suppression (aOR=0.69; p<0.05 older adolescent). Increasing facility-level viral load testing reduced the likelihood of non-retention in care, while baseline regimen TDF/3TC/EFV or NVP increased the likelihood of viral suppression.Conclusions Differences in characteristics of healthcare facilities accounted for observed disparities in retention in care and, to a lesser extent, disparities in viral suppression. An optimal combination of individual and health-services approaches is, therefore, necessary to reduce disparities in the health and wellbeing of ALHIV.What is already known?Adolescents and youths living with HIV have worse care and treatment outcomes compared to other groupsSignificant disparity in care and treatment outcomes exist between different adolescent and youth subgroupsWhat are the new findings?Differences in characteristics of healthcare facilities delivering services are associated with disparities in outcomes within and across adolescent and youth age-groups.What do the new findings imply?An optimal combination of individual and health-services approaches is necessary to reduce disparities in the health and wellbeing of adolescent and youths living with HIV.Competing Interest StatementThe authors have declared no competing interest.Funding StatementOkikiolu Badejo received doctoral research funding from the Belgium Directorate-General for Development Cooperation (DGD) awarded through the Institute of Tropical Medicine Antwerp, BelgiumAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institute of Tropical Medicine, Antwerp APIN Public Health Institute, NigeriaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are not publicly available but can be obtained upon request from APIN-PEPFAR clinical database ER -